Clinicopathological outcomes of preoperative chemoradiotherapy using S-1 plus Irinotecan for T4 lower rectal cancer.

Abstract

To investigate the clinicopathological outcomes of patients with T4 lower rectal cancer treated using preoperative chemoradiotherapy with S-1 plus Irinotecan. Between 2005 and 2011, 35 patients with T4M0 lower rectal cancer, diagnosed initially as T4a in 12 and as T4b in 23, were treated with 45Gy of radiotherapy concomitantly with S-1 plus Irinotecan. The median follow-up period was 50.6months (range 2-123months). A total of 32 patients (91.4%) completed the radiotherapy and 26 (74.3%) completed the full chemotherapy regimen. Radical surgery was then performed in 33 (94.3%) of the 35 patients after the exclusion of two patients, who had macroscopic residual disease. The pathological diagnosis was downstaged from T4a to ypT0-3 in all 12 of those patients (100%) and from T4b to ypT0-4a in 20 of those 23 patients (87.0%). The tumor regression grade of 1a/1b/2/3 (complete response) was 10/8/15/2, respectively. In terms of long-term survival, the 5-year local relapse-free survival rate was 74.8% and the recurrence-free survival rate was 52.0%. This regimen may result in favorable downstaging. Moreover, in this series, pathological evidence of involvement of adjacent organs was rare following preoperative chemoradiotherapy, in the patients with disease diagnosed as T4b at the initial staging.